Status:
COMPLETED
Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Schizophrenia
Psychotic Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The primary objective is to compare effectiveness of ziprasidone treatment to current treatments (haloperidol, olanzapine or risperidone) measured by change in Brief Psychiatric Rating Scale (BPRS) sc...
Eligibility Criteria
Inclusion
- Primary diagnosis of schizophrenia or schizoaffective disorder, using DSM-IV criteria.
- Currently receiving either haloperidol, olanzapine or risperidone within -/+ 25% of the recommended daily dose (as delineated by the medication's package insert
Exclusion
- Resistance to conventional antipsychotic drugs
- With antipsychotic agents other than olanzapine, risperidone or haloperidol at start of treatment regimen within 12 hours prior to first dose of study drug
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
294 Patients enrolled
Trial Details
Trial ID
NCT00137020
Start Date
November 1 2004
End Date
April 1 2006
Last Update
February 21 2021
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Alexandria, Egypt
2
Pfizer Investigational Site
Asyut, Egypt
3
Pfizer Investigational Site
Cairo, Egypt
4
Pfizer Investigational Site
Tanta, Egypt